“We are in a phase of great invention as we work our way through the different means to engineer a patient’s own immune cells to fight cancer.” – Jim Beltzer, Ph.D., principal Consultant with Latham BioPharm Group
Read about the current state of product and process development in autologous cell therapy as well as what is needed to meet the demand for these life-saving treatments in the article “Challenges of Commercial-Scale Autologous CART-T Cell Manufacturing” written by Jim Beltzer, Sridhar Venkatesan, Tianna Coon, Lauren Schoukroun, Joe Rininger.
“The field of cell therapy is relatively young and advancing quickly. Both product and process innovations are needed for bringing new cell therapies to market. Success requires a deep understanding of cell biology to modify cells of interest and expand cultures to sufficient numbers for treatment.” commented BioProcess International, who published the article in their eBooks on August 21, 2024.
Read the full article here https://www.bioprocessintl.com/cell-therapies
